Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study
- 11 February 2021
- journal article
- letter
- Published by Elsevier BV in Journal of Infection
- Vol. 82 (6), 276-316
- https://doi.org/10.1016/j.jinf.2021.02.011
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial ResultsThe New England Journal of Medicine, 2021
- Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialThe Lancet, 2020
- Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future PerspectivesFrontiers in Pharmacology, 2020
- Características clínicas de los pacientes hospitalizados con COVID-19 en España: resultados del Registro SEMI-COVID-19Revista Clínica Española, 2020
- Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19Journal of Infection, 2020
- A Trial of Lopinavir–Ritonavir in Covid-19The New England Journal of Medicine, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- How will country-based mitigation measures influence the course of the COVID-19 epidemic?The Lancet, 2020